Paper Details

  1. Home
  2. Paper Details

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF<sup>V600E/K</sup></i> -mutant Solid Tumors.

Author: AsciertoPaolo A, CarlinoMatteo S, DummerReinhard, ElezElena, LebbéCeleste, PatelSapna, PickardMichael D, SandorVictor, SienaSalvatore, SullivanRyan J, TanDaniel S W, WeberJeffrey, WollenbergLance

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with BRAF V600E-mutant melanoma.
Paper Details　
Original Abstract of the Article :
PURPOSE: This open-label, dose-finding phase Ib/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with PATIENTS AND METHODS: In phase I, the recommended phase 2 doses (RP2D) were establish...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-19-3550

データ提供：米国国立医学図書館（NLM）

Targeting Cancer with a Two-Pronged Approach

Cancer, a formidable foe, requires innovative treatment strategies. This research explores the potential of combining two targeted therapies, encorafenib and binimetinib, for the treatment of BRAFV600E/K-mutant solid tumors. Like a desert traveler equipped with a map and a compass, researchers investigated the safety and effectiveness of this combination therapy, finding promising results in terms of tumor response and overall survival. This research offers hope for new and effective treatment options for patients with these specific types of cancer.

A Promising Oasis in the Desert of Cancer Treatment

The clinical trial demonstrated that the combination of encorafenib and binimetinib was well-tolerated and showed encouraging activity in patients with BRAFV600E/K-mutant solid tumors. It's like discovering a hidden oasis in the heart of a desolate desert, offering a new source of life and hope for those facing the challenges of cancer. This research highlights the potential of targeted therapy combinations for treating cancer, offering a personalized approach to combatting this complex disease.

The Desert of Cancer

The journey through the desert of cancer can be a difficult and uncertain one. This research provides a beacon of hope, showcasing the potential of targeted therapies to combat this challenging disease and improve outcomes for patients.

Dr.Camel's Conclusion

The development of this combination therapy represents a significant step forward in the fight against cancer. It's like finding a new path through a treacherous desert, offering a potential solution to a complex challenge.

Date :
  1. Date Completed 2021-11-25
  2. Date Revised 2021-11-25
Further Info :

Pubmed ID

32669376

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-19-3550

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.